{'fraction_non_alphanumeric': 0.033659066232356136, 'fraction_numerical': 0.03257328990228013, 'mean_word_length': 5.492957746478873, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Assembly of a cohort of children treated for acute myeloid leukemia at free‐standing children's hospitals in the United States using an administrative database

Pediatric Health Information System data were used to establish a multi‐center cohort of 1,686 children treated for newly diagnosed acute myeloid leukemia (AML). The cohort assembly process, which included myeloid leukemia ICD‐9 discharge diagnosis codes and manual review of induction chemotherapy, was validated by chart review at a single institution. The use of ICD‐9 codes alone resulted in a poor positive predictive value (PPV; 31%). Inclusion of the results from the chemotherapy review improved the PPV to 100% without compromising sensitivity (95.7%). This cohort provides a reliable source for future comparative effectiveness and clinical epidemiology studies in pediatric AML. Pediatr Blood Cancer 2013; 60: 508–511. © 2012 Wiley Periodicals, Inc.